Prospects for vaccine protection against HIV-1 infection and AIDS.
about
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designAn alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine DevelopmentHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesHIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptorsGlycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicityReplication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesMulticlade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primatesImmunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityRecommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesB cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- miceElicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination.Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virusCurrent progress in the development of a prophylactic vaccine for HIV-1.Non-human primate models for AIDS vaccine research.Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein TrimersResting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy.Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeysImproved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines.Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Progress in the development of an HIV vaccine.Human immunodeficiency virus: scientific challenges impeding candidate vaccines.Memories of virus-specific CD8+ T cells.Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease ControlSusceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.
P2860
Q24679395-69C2A06F-72E7-41D9-A5C8-3369059A877AQ25256583-5113342F-8253-4E20-AB9E-FFA9F481449EQ27477561-4495A585-2C00-40CB-88C5-786EEE41D20AQ29619015-F9EB421B-5B21-446F-8B75-D5DC466F11D7Q30226766-DEF592FD-7C3E-425D-A674-B8C74A2C573EQ30360326-46373940-5BC4-4C45-BFAF-AB4215DC4988Q30410411-60A5F92B-B682-4C29-BDE4-289EAABC09A9Q30558705-140C52BF-B475-4CFF-8363-BDD9BA5A5843Q33323199-3686795F-FCFB-4E3A-B645-3CEE45ADAE36Q33686890-BE44B890-6AA7-40F6-9173-CD90099AC40AQ33717525-2C8040D4-0AA2-486A-8E16-A5F39C793E70Q33754985-F490435C-5EF2-47ED-8D1E-50F27222C6DAQ33780685-A253405E-98C5-45A2-846A-85804E27BEF6Q33834916-0CA8FD69-E987-4A83-855D-D35E266AFAA0Q33843103-D631D913-93F1-42AE-8314-7B9B2809261DQ33883854-DAEBA9CD-1D74-4D92-B5A2-64B115F0210FQ33908767-DA809F93-3E70-4FAB-B0EB-26C5D0F5B980Q33911935-829BE6FB-CB94-417B-81D3-877976158215Q34008741-CE6FE458-1309-4466-96DE-7E2A7FE86B4FQ34045678-FB0DF500-EDC9-4FF5-9906-50397C1A58EFQ34100221-22B706E2-4B1A-486A-8B17-831F2885C378Q34355284-C126C2D9-C6E7-4B04-9093-061E8F685F86Q34468698-15116D91-418C-4362-A095-8B7C72515003Q34502108-96FD3B38-D0DF-4B8A-8722-A818BEBB9E69Q34715769-AC1150C2-9D68-4A50-A3A9-0A1A103575E7Q34807480-65F3AE3E-E7F6-4F49-A457-B4A306A58808Q34857454-648B0A4A-12BD-4C2D-AB3A-3240E28A46B4Q35123128-A41A32B6-A011-4CB2-BAA4-A362CC379189Q35140032-B84D1F20-9551-49D6-BE85-84AD41A9C21BQ35149425-DD40B703-E4B5-45B8-96B0-E0297370C3CAQ35155380-DED9D9E0-583E-48A5-BBFC-D83C0ED54E8FQ35182263-F91B3DC0-5FD8-4A10-AA31-93D851B08477Q35208657-DE7CA1B8-0F5E-4B33-87FE-B7924D6446FCQ35581128-40EC4DAE-D431-4186-897F-98E5DD7E7204Q35589136-B6628F04-A097-414E-8BD7-EB9BD5A2D269Q35734111-E15420B6-02A1-4BFD-8469-E41738B8F5E1Q35909944-7C17C9F5-2E1B-4157-B6D3-28EBABB160E7Q35947805-5155B037-79DC-406D-9E5B-BE3F06B523A2Q35995081-91538BD7-AB3E-4DAF-8452-62478CF34483Q36099050-EBDD1F3A-910B-43EB-A6CF-903C7847B043
P2860
Prospects for vaccine protection against HIV-1 infection and AIDS.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prospects for vaccine protection against HIV-1 infection and AIDS.
@ast
Prospects for vaccine protection against HIV-1 infection and AIDS.
@en
Prospects for vaccine protection against HIV-1 infection and AIDS.
@nl
type
label
Prospects for vaccine protection against HIV-1 infection and AIDS.
@ast
Prospects for vaccine protection against HIV-1 infection and AIDS.
@en
Prospects for vaccine protection against HIV-1 infection and AIDS.
@nl
prefLabel
Prospects for vaccine protection against HIV-1 infection and AIDS.
@ast
Prospects for vaccine protection against HIV-1 infection and AIDS.
@en
Prospects for vaccine protection against HIV-1 infection and AIDS.
@nl
P1476
Prospects for vaccine protection against HIV-1 infection and AIDS.
@en
P2093
Norman L Letvin
P356
10.1146/ANNUREV.IMMUNOL.20.081501.094854
P577
2001-10-04T00:00:00Z